Yousif Capital Management LLC Lowers Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Yousif Capital Management LLC decreased its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 0.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 91,077 shares of the biotechnology company’s stock after selling 667 shares during the period. Yousif Capital Management LLC’s holdings in ADMA Biologics were worth $1,562,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in ADMA. Hollencrest Capital Management bought a new position in ADMA Biologics during the 3rd quarter valued at approximately $30,000. Larson Financial Group LLC bought a new position in shares of ADMA Biologics during the third quarter valued at $31,000. National Bank of Canada FI purchased a new position in shares of ADMA Biologics in the 3rd quarter worth about $35,000. GAMMA Investing LLC boosted its stake in ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 967 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd purchased a new stake in ADMA Biologics during the 3rd quarter valued at about $62,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Trading Down 0.3 %

ADMA Biologics stock opened at $15.84 on Thursday. The business has a 50-day simple moving average of $17.50 and a two-hundred day simple moving average of $17.77. ADMA Biologics, Inc. has a 52-week low of $5.02 and a 52-week high of $23.64. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The company has a market cap of $3.74 billion, a P/E ratio of 56.57 and a beta of 0.75.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. HC Wainwright increased their price target on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a report on Friday, November 8th. Raymond James increased their target price on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a research note on Friday, November 8th.

Insiders Place Their Bets

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now owns 199,433 shares in the company, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.70% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.